CADM1 and cervical carcinoma: Hesselink and Bierkens developed an objective nonmorphological molecular method of CADM1/MAL methylation as a cervical cancer screening marker with high sensitivity (ranging from 100% to 60.5%) for CINIII and patients with cervical cancer 124, 125.